Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings of $0 in Q2 FY2026
Q2 FY2026 retained earnings was $0.
Context
- Retained earnings amounted to 0.0% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (181.86M) USD
- Year-over-year change
- —
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (181.86M) | — |
Retained Earnings vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 retained earnings of $0 is the highest of the 5 companies compared; the peer median is -$603.95M.
- Retained earnings amounts to 0.0% of total assets for COAG, versus a peer median of 138.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $0 | — | — | 0.0% |
| Mar 2026 | -$310.28M | -2.6% | — | 569.6% | |
DMRADamora Therapeutics, Inc. | Mar 2026 | -$515.15M | -83.9% | — | 96.2% |
IRONDisc Medicine, Inc. | Sep 2026 | -$692.76M | -54.1% | — | 99.0% |
| Mar 2026 | -$1.38B | -17.8% | — | 177.5% | |
| Peer median (excluding COAG) | -$603.95M | -35.9% | — | 138.3% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.